Corticosteroid Therapy for COVID-19-Related ARDS Corticosteroid Therapy for COVID-19-Related ARDS
What role do corticosteroids have in the treatment of ARDS caused by COVID-19? How might this therapy impact the risk of in-hospital mortality in these patients?Critical Care (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 19, 2021 Category: Intensive Care Tags: Critical Care Journal Article Source Type: news
Corticosteroid Therapy for COVID-19-Related ARDS Corticosteroid Therapy for COVID-19-Related ARDS
What role do corticosteroids have in the treatment of ARDS caused by COVID-19? How might this therapy impact the risk of in-hospital mortality in these patients?Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 19, 2021 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news
DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to the deterior...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
THOUSAND OAKS, Calif., Dec. 21, 2020 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticoster... Biopharmaceuticals Amgen, AstraZeneca, tezepelumab, asthma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 22, 2020 Category: Pharmaceuticals Source Type: news
Position statement: Use of investigational immunomodulatory medicines for COVID-19 Interim support for UK hospital clinicians, RCP
Key messages
• A subset of patients with COVID-19 may experience an exaggerated hyperinflammatory response
• COVID-19 associated hyperinflammation predominantly involves the lung however may progress to secondary haemophagocytic lymphohistocytosis (sHLH) which is a systemic and multi-organ condition with significant morbidity and mortality
• CTAG strongly recommends systemic corticosteroids for patients who fit definitions of WHOdefined severe or critical COVID-19, or in patients who otherwise have a new oxygen requirement
• CTAG also recommends not to use corticosteroid therapy in patients with WHO-defined...
Source: Current Awareness Service for Health (CASH) - December 21, 2020 Category: Consumer Health News Source Type: news
